Overview

The brain contains a diverse population of cells, including neurons and various glial cells—astrocytes, oligodendrocytes, and microglia—each with distinct cholesterol requirements and manufacturing capabilities. Early work with cultured cells derived from animal models indicates that neurons predominantly derive their cholesterol from glial cells. Cultured glial cells from chicken embryos are able to manufacture two- to three-fold more cholesterol than neurons [23], and glial cells transfer cholesterol to other cells via ABC transporters (discussed in detail below) [24, 25]. In the absence of glial cells, rat neurons synthesize sterols at a lower rate and are unable to compensate for the cholesterol deficit [24]. However, neurons in glial co-cultures drastically downregulate the expression of the early cholesterol biosynthesis pathway enzyme, SQS, suggesting the reduced capacity for cholesterol synthesis [24, 26]. Neurons in culture rarely esterify newly synthesized cholesterol for storage, and their cholesterol demand is met by exogenous uptake [24, 25].

The brain appears to switch between the use of the post-lanosterol Bloch and K-Rs (summarized in Table 1). Curiously, in developing brains from all mammalian species reported, including humans, desmosterol transiently accumulates to constitute up to 30% of total brain sterols [27]. The post-translational repression of DHCR24 by progesterone is proposed to cause the desmosterol build-up, to facilitate the enrichment and distribution of membrane sterols in the developing brain [27]. Indeed, sterol profiles of embryonic mice cells indicate desmosterol and other Bloch sterol accumulation in neurons and astrocytes [28]. By contrast, in vitro work showed that post-natal rat neurons accumulate 7-dehydrocholesterol and lathosterol, precursors of the K-R, whilst astrocytes retain Bloch intermediates, namely the immediate cholesterol precursor, desmosterol [24]. Oligodendrocytes and microglia seem to favor the use of the K-R, as these cells derived from post-natal rats have higher proportions of lathosterol and 7-dehydrocholesterol than astrocytes and neurons [24]. Evidently, there is a dynamic exchange in preference for these two pathways within the brain throughout the life of a vertebrate. The characteristics of cholesterol production in brain cells have been studied in specific cell types, with findings summarized in Table 1 and discussed in detail below.

Neurons

In neurons, cholesterol is an important component of myelin and the membranes of synapses, dendrites, and axons, where it regulates membrane fluidity [29]. Neurons can synthesize their own cholesterol to a limited extent. Murine neurons express mRNA transcripts and proteins of components of the cholesterol synthesis pathway, including those for the early enzyme SQS, the post-lanosterol enzymes NSDHL and LDM, and the terminal enzyme DHCR24 [24, 42]. Neuron-rich areas of the mouse hippocampus express higher amounts of cholesterol biosynthetic enzyme mRNA transcripts than astrocyte-rich areas [44], although this may not translate to protein expression or enzyme activity.

The ability of neurons to produce cholesterol is dependent on the life stage of the vertebrate. Developing neurons actively and locally synthesize cholesterol with the endogenous sterol pool increasing over time [28]. A comparison of cholesterol synthesis in neurons between adult versus embryonic mice reveals striking differences. Adult mice with a neuron-specific cholesterol synthesis ablation due to a deletion of SQS, are phenotypically similar to wild-type mice, indicating that neurons in adults do not contribute to the overall cholesterol synthesis in the brain [31]. However, ablation of cholesterol synthesis via conditional SQS knockout in murine neuronal precursor cells is perinatally lethal, with embryos developing smaller brains [30]. Neurons compensate by promoting angiogenesis to increase lipoprotein uptake [30]. Together, these studies indicate that cholesterol synthesis predominantly occurs in neuron precursor cells or neurons during early development.

Astrocytes

Astrocytes are thought to be the main hubs for cholesterol synthesis in the brain, with most of the sterol supplied to neurons [45]. These glial cells support neuronal growth and development during childhood, and neuronal maintenance throughout adulthood [32]. Cholesterol is synthesized in the endoplasmic reticulum and rapidly transported to the plasma membrane in vesicles and via apolipoprotein-mediated systems [32]. During development, astrocytes maintain strict control of their endogenous cholesterol homeostasis [28].

Several lines of evidence support the idea that astrocytes are the main cholesterol manufacturers in the brain. Murine studies have shown that transcriptional control of cholesterol biosynthesis is more prevalent in astrocytes as SREBP-1 is more highly expressed in the astrocytes compared to neurons [26]. In addition, between murine astrocytes, oligodendrocytes, and microglia, astrocytes express the highest levels of transcripts of the cholesterol synthesis enzymes throughout the entire biosynthetic pathway [42].

The importance of astrocyte cholesterol synthesis in the brain is underscored by the dramatic phenotypic changes observed when the process is disrupted in murine models. The complete inactivation of the murine equivalents of HMG-CoA reductase and SQS, HMGCR, and SQS, via mutational gene disruptions is embryonically lethal [46, 47]. Conditional mutations of Sqs are not lethal to mice but result in many neurological defects. Mice with astrocyte-specific SQS mutations have a limited ability to secrete cholesterol from astrocytes. In addition, neuronal synapses and synaptic vesicles are unable to mature, suggesting that neurons are dependent on astrocyte-derived cholesterol to support the formation of synapses [26]. Evidently, cholesterol sourced from astrocytes is critical for neuronal function.

Oligodendrocytes

Oligodendrocytes wrap axons with cholesterol-rich myelin, providing the electrical insulation necessary for a process called saltatory conduction. Electrical impulses can also skip between nodes of the axon not insulated by myelin, speeding up the arrival of the signal to the synaptic terminal [36]. Oligodendrocytes synthesize substantial amounts of cholesterol for myelin formation and maintenance. Like astrocytes, murine oligodendrocytes express high levels of cholesterogenic transcripts, especially those for the post-lanosterol enzymes, LDM, and DHCR24 [42]. Cholesterol in oligodendrocytes is synthesized de novo via a feed-forward process involving phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling [48].

Myelin contains a large proportion of the brain’s cholesterol store, with estimates from murine models indicating that 80% of the brain’s cholesterol resides within myelin [35]. Rodent studies indicate that the timing of myelination correlates with total brain cholesterol accumulation during the first three weeks of life [9, 35]. Nevertheless, myelination and oligodendrocyte maturation continue during the adult life stages of a mammal [37].

A disruption in oligodendrocyte cholesterol synthesis reduces the rate of CNS myelination and perturbs motor function and coordination [38]. Cholesterol-deficient oligodendrocytes can compensate through cholesterol uptake from neighboring cells [38]. Cholesterol availability is a limiting factor of myelin growth during development, with cholesterol synthesis in oligodendrocytes especially crucial during early life stages. Myelination continues throughout adulthood for the growth and repair of white matter tissue [37]. The regulation of this process is dynamic and cholesterol crosstalk occurs between astrocytes and oligodendrocytes. An in vitro study indicates that astrocytes from grey matter (an area of the brain rich in neuronal bodies) rather than white matter (an area in the brain rich in myelinated axons) are able to secrete cholesterol and support myelination [39]. Clearly, when cholesterol supply is disrupted, astrocytes are a critical source of cholesterol necessary for myelination. Further studies are warranted to explore how cells can re-route neural circuits during myelin repair and what signaling processes are involved. Such studies may offer novel insights into the pathophysiology of neurological diseases such as multiple sclerosis, which is characterized by immune-mediated demyelination and loss of axons [49].

Microglia

Microglia are phagocytic immune cells in the CNS that engulf lipid debris and trigger apoptosis. Microglia survey and respond to the state of synapses, in a process known as synaptic pruning, which is particularly active in the developing brain [41]. A sub-population of microglia is responsible for the removal of myelin debris and remyelination [40]. Microglia adapt and respond to many environmental cues, such as neuroinflammation in diseases such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. Cellular lipid composition influences microglial function [33, 40]; while cholesterol is essential for microglial survival [43], excessive intracellular cholesterol accumulation in aged or pro-inflammatory microglia in multiple sclerosis is toxic and impairs the ability for microglia to phagocytose myelin debris and repair myelin [50, 51].

Microglia do not synthesize large amounts of cholesterol since cholesterogenic enzymes in murine microglia exhibit a low transcription profile compared to other glial cells [42]. Instead, microglia derive most of their cholesterol from neighboring astrocytes [43]. However, the synthesis of cholesterol intermediates is more critical in microglia. A recent study found that desmosterol, the immediate cholesterol precursor in the Bloch pathway, is critical for the repair of demyelinated lesions [42]. Desmosterol activates LXR signaling for cholesterol efflux to resolve inflammation and promote oligodendrocyte differentiation [42]. The synthesis of other sterol intermediates could also play a role in microglia function; however, this requires further investigation.

Apolipoproteins: ApoE and clusterin

ApoE is the most abundant lipoprotein in the CNS and is synthesized locally chiefly by astrocytes, partially by microglia, and minimally by neurons [58]. ApoE oligomers cannot be complex with lipids. However, upon monomerization, the lipid-binding region is exposed and the protein is able to bind lipids [59–62]. Lipidation of ApoE by cholesterol and phospholipids is mediated by ABC transporters. The resultant HDL-like particles are then secreted by astrocytes into the interstitial fluid [15]. Fully lipidated ApoE undergoes a conformational change to enable interaction with its receptors for cellular uptake [63].

Clusterin is the second major apolipoprotein present in the brain [64]. It is a multifunctional glycoprotein that is distributed in lipoproteins and ubiquitously expressed in the extracellular matrix of many tissues throughout the body and in the CNS [53, 65]. The protein consists of two linked polypeptide chains, which can be configured into different proteoforms by the presence or absence of glycosylation [66]. The proteoform structure confers specificity in the protein’s subcellular localization and function [66]. Intracellular clusterin regulates apoptosis [67, 68] and mitochondrial function [69, 70] and is not known to transport cholesterol. Only the most mature and glycosylated form of clusterin is secreted from the cell and is a known component of circulating peripheral lipoproteins and HDL-like particles in the brain [71]. Clusterin is expressed by both astrocytes and neurons [72], as well as the ependymal cells lining the ventricle [72, 73]. Clusterin is required for lipid trafficking [74] and is able to bind to the LRP2 receptor in vitro [75], with lipidated clusterin enhancing the binding affinity [65]. The interplay between the role of clusterin as a cholesterol carrier and its intracellular functions is an avenue for further exploration.

Other lipoproteins present in the brain, albeit in smaller quantities, include the peripherally-derived apolipoproteins ApoA-I and ApoA-II, and ApoD, ApoC-I, ApoA-IV, and ApoH which are synthesized within the brain. Their roles in cholesterol transport within the CNS are poorly understood [76, 77].

Cholesterol trafficking genes are implicated in late-onset Alzheimer’s disease

Three major isoforms exist for ApoE in humans, ApoE2, ApoE3, and ApoE4. The ApoE4 isoform, as well as a single nucleotide polymorphism (SNP) in the clusterin gene (CLU) are associated with elevated risk for Alzheimer’s disease [64, 78, 79], suggesting that cholesterol trafficking may be dysregulated in patients with the disease. Indeed, cholesterol abnormalities have been observed in these patients; plasma membranes of brain cells are enriched with cholesterol, and these cholesterol levels persistently increase throughout the course of the disease [80, 81].

The ApoE4 isoform correlates with impaired clearance of amyloid-beta (Aβ) peptides [82], which are a characteristic feature of the Alzheimer’s brain and have been shown to contribute to neurotoxicity and neurodegeneration [79]. The ApoE4 isoform does not operate as efficiently in the delivery of cholesterol to neurons as compared with the ApoE3 isoform [72]. ApoE isoform-dependent processing of Aβ has been recently reviewed by Chai et al [82]. In addition to its role as a cholesterol carrier, secreted clusterin may serve as a protein chaperone outside the cell, in a similar manner to heat shock proteins [83]. Clusterin can be complex with Aβ to mediate endocytosis and transcytosis [84] and is thought to promote cell survival [64]. An Alzheimer’s disease-associated SNP in clusterin affects the alternative splicing of the gene, decreases its expression, and likely reduces Aβ clearance [64]. Cholesterol and Aβ aggregate carried by ApoE and/or clusterin bind with the microglial receptor, TREM2, in human cells cultured in vitro [55], suggesting that cholesterol and Aβ aggregates can be cleared by microglia.

The precise molecular mechanisms of how the different ApoE isoforms and clusterin transport cholesterol in healthy brains versus in Alzheimer’s disease still require further examination. The lipid and apolipoprotein composition of extracellular vesicles from healthy and diseased brains could be analyzed by comprehensive ‘omic’ studies [85]. These vesicles are reflective of intracellular contents, providing a non-invasive method of study. Proteomic and lipidomic studies can be coupled with reductionist approaches with in vivo models to understand the nuances of apolipoprotein-mediated cholesterol transport in healthy versus diseased brains. Further elucidation of structural and conformational changes of ApoE and clusterin upon cholesterol-binding is not only important for understanding cholesterol transport in the brain but may also facilitate future drug target design for Alzheimer’s disease.

Transport of brain cholesterol by ABC transporters

The distribution of cholesterol and other lipids within the brain is facilitated by the actions of ABC transporters. These transporters are widely expressed throughout the body and utilize the energy generated from ATP hydrolysis to translocate a broad variety of endogenous and exogenous substrates across cell membranes. In humans, the ABC transporter superfamily encompasses 48 structurally similar proteins categorized into seven families designated ABCA to ABCG. The majority of these are full transporters, exhibiting a four-domain composition consisting of two cytoplasmic nucleotide-binding domains (which house the signature LSGGQ amino acid motif) and two transmembrane domains (which dictate the ligand specificity) [86]. Half transporters, such as ABCDs and ABCGs, contain a single nucleotide-binding domain and a single transmembrane domain and must form homo- or hetero-dimers to be fully functional. Several ABC transporters that are expressed in the brain are also known to transport lipid substrates (Table 2). While many of these have only been investigated with respect to their lipid-transporting capacity in the periphery and thus whether corresponding functions exist for them in the brain remain unexplored, important roles have been identified for ABCA1, ABCG1, and ABCG4 in brain cholesterol transport.

SREBP-mediated transcriptional control for brain development and function

SREBP-mediated transcription is required for regulating normal levels of cholesterol synthesis and is critical for the survival of embryonic cells [145, 146]. As one of the main cholesterol synthesizers in the brain, astrocytes require SREBP to upregulate cholesterol biosynthetic enzymes, and its activity is modulated by SCAP [17, 147, 148]. The cholesterol generated in astrocytes can then be taken up by neurons for neuronal growth and synaptic maintenance. Mice with SREBP-2 specific knockouts in CNS astrocytes survive after birth, but display microcephaly, impaired brain development, and behavioral and motor defects [34]. Similarly, neurological deficits and early mortality are seen in mice with a loss of astrocytic SCAP [26, 149]. In neuron-astrocyte co-cultures, SREBP-2-regulated transcription in astrocytes is critical for neurite outgrowth [34]. Curiously, mice with a loss of astrocytic SREBP2 display metabolic defects including adiposity reduction and a shift in their metabolism towards carbohydrate oxidation, driven by increased glucose oxidation by the brain [34]. A complex crosstalk between carbohydrate and cholesterol pathways may be present in the brain, and extricating the underlying mechanisms involved is important for understanding the potential relationships between brain health, neurodegenerative conditions, and metabolic disorders.

To date, the importance of SREBP transcription factors in other brain cell types has not been examined closely. SREBP is likely to be critical for oligodendrocytes and developing neurons, which are other major sites for cholesterol synthesis in the brain. Mice with a whole-body disruption of one Insig isoform were viable and showed close to normal lipid metabolism, suggesting potential compensation by the other Insig isoform or other mechanisms [150–152]. Nevertheless, an animal model with CNS-specific perturbations to both Insig-1 and Insig-2 isoforms may provide further insights into the regulation of the SREBP pathway in the brain.

LXR-mediated transcriptional control for brain development and function

In the brain, LXR activation directly upregulates the transcription of cholesterol transporters, and indirectly downregulates cellular cholesterol uptake. LXR controls the transcription of ApoE and ABC transporters including ABCA1 and ABCG1 [153], which lipidated apolipoproteins for intercellular cholesterol distribution [15]. Meanwhile, LXR also transcriptionally upregulates the gene, inducible degrader of the LDLR (Idol) [154]. Idol is an E3 ubiquitin ligase that specifically targets LDLR for proteasomal degradation and thus decreases cholesterol uptake into the cell. Disruption of both LXRα and β isoforms in mice leads to pathological changes in the brain, including lipid accumulation and neurodegeneration, with significant downregulations in the mRNA levels of direct LXR targets, including ABCA1 and ABCG1 gene expression, as well as indirect LXR targets, including LDLR, SREBP-1c, and SREBP-2 genes and cholesterol synthesis genes [155].

The LXR pathway itself is regulated by an endoplasmic reticulum-bound transcription factor, nuclear factor erythroid 2 related factor 1 (NRF1). Under low cholesterol conditions, NRF1 translocates into the nucleus and represses the LXR pathway, preventing cholesterol removal. However, in situations of cholesterol excess, cholesterol-binding retains the transcription factor in the endoplasmic reticulum, resulting in a de-repression of LXR activity and activation of cholesterol export [156]. Thus, NRF1 is a master regulator of the LXR pathway, and, indeed in the mouse liver, it exerts a protective effect by preventing cholesterol accumulation and suppressing inflammation. Although, NRF1-mediated control of cholesterol levels has not been well investigated in the brain, disrupting its activity in mouse neurons leads to neurodegeneration [157], suggesting the importance of NRF1 in this organ.

During brain development, LXR signaling influences neuronal migration, where cells arrange themselves in appropriate spatio-temporal patterns to optimize neuronal circuit function [158]. When LXRβ is knocked out in mice, neuronal migration is unsuccessful and disorganized [159]. This could occur via LXR-mediated modulation of the Reelin signaling pathway, which is responsible for controlling neuronal migration and the formation of cellular layers [160]. The LXR target, Idol, has been shown to regulate expression of the Reelin and lipoprotein receptors, very-LDLR (VLDLR), and ApoE receptor 2, in vitro [18, 161]. Correspondingly, in vivo pharmacological activation of the LXR pathway in mice increases Idol expression and decreases VLDLR levels [18]. Evidently, neuron migration in developing brains and cholesterol transport is coordinated by the same cellular machinery. Consequently, the crosstalk between LXR-mediated cholesterol transport and Reelin signaling is a potential avenue for research.

Myelin production and repair are also regulated by LXR signaling. Thinner myelin sheaths, and altered motor coordination and spatial learning linked to cerebellar deficits, are seen in LXRα/β-double knockout mice [162]. Primary murine oligodendrocytes in culture require LXR for maturation [162], and during differentiation, LXRβ expression is increased at both neonatal and adult life stages. Treating differentiating primary murine oligodendrocytes with a synthetic LXR ligand-induced cholesterol efflux [19]. Oligodendrocyte differentiation is required for myelin repair and the LXR signaling pathways could be a potential therapeutic target for treating demyelination in multiple sclerosis [49].

Esterification

Excess cholesterol can be esterified and stored within intracellular organelles known as lipid droplets. Within the brain, cholesteryl esters only constitute ~1% of total cholesterol content. Esterification occurs through the action of acyl-CoA: cholesterol acyltransferase 1 (ACAT1), which is localized in the endoplasmic reticulum [25]. ACAT1 expression and activity have been detected in neurons, but not in glial cells [163]. However, cholesterol esterification by ACAT1 may be induced in astrocytes under conditions of cholesterol loading or absence of ApoE [130]. Not only do lipid droplets protect cells from toxic accumulation of excess lipids, but they also serve as reservoirs of cholesteryl esters and triglycerides, which can be hydrolyzed into free cholesterol and fatty acids respectively, to fulfill cellular needs for cell signaling, membrane formation, and energy production [164, 165].

Direct export from brain

Cholesterol may be eliminated directly from the brain complexed with apolipoproteins. Cholesterol bound to ApoA-I or ApoE is released by glial cells into the CSF, and subsequently cleared from the brain via CSF bulk flow [166]. However, this only constitutes a minor elimination pathway as it is estimated to remove 2 mg of cholesterol each day [166].

Although it is widely recognized that cholesterol is unable to pass through the blood-brain barrier owing to the presence of tight junctions [167], interestingly, one study has reported direct transport of free cholesterol across the blood-brain barrier via ABCA1 in mice [168]. It also remains possible that physiological and morphological changes to the blood-brain barrier as a result of age or neurodegenerative disease may compromise its permeability, rendering a greater likelihood of leakage of substances, including cholesterol, into and out of the brain [169]. Indeed, increased leakage of oxysterols out of the brain at the blood-brain barrier has been reported in pericyte-deficient mice [170].

Conversion into 24S-HC

The third and most quantitatively significant route of elimination of cholesterol from the brain involves conversion into the oxysterol, 24S-HC. Excess cholesterol undergoes 24S-hydroxylation by the CYP enzyme, CYP46A1 (also known as cholesterol 24-hydroxylase), producing a less hydrophobic molecule that traverses lipophilic membranes much more readily than cholesterol [25, 171, 172]. Deletion of CYP46A1 in mice reduces cholesterol efflux from the brain by 64%, highlighting the importance of this elimination pathway [172]. CYP46A1 is localized to neurons of the brain. Immunohistochemical analyses have identified its expression in the endoplasmic reticulum of cortical pyramidal cells, Purkinje cells of the cerebellum, and hippocampal and thalamic neurons [173, 174], thus implicating neurons as the primary site for the initiation of cholesterol turnover in the brain. Despite this, some studies have demonstrated that CYP46A1 expression may occur in microglia and astrocytes in circumstances of brain injury or disease, however, its functionality at these sites has not yet been confirmed [175–178]. Although it is generally accepted that 24S-HC can passively diffuse across the neuronal membrane, Matsuda et al [94] demonstrated that 24S-HC may be actively exported from SH-SY5Y neuronal cells by ABCA1 in the presence of HDL.

Approximately 1% of 24S-HC flux from the brain occurs via the CSF, while the remaining 99% occurs via diffusion through the blood-brain barrier [179]. Active transportation by organic anion transporter proteins can also facilitate the removal of 24S-HC at the blood-brain barrier [180]. 24S-HC is released into circulation at a rate of 6–7 mg/day and delivered to the liver via LDL and HDL for biliary excretion [77, 167, 181]. In healthy individuals, the magnitude of brain flux closely reflects that of hepatic uptake, indicating that 24S-HC production is exclusive to the brain [181]. However, circulating levels of 24S-HC can be affected by age and the brain-to-liver size ratio [182].

24S-HC

24S-HC is one of the most abundant oxysterols in the brain [15]. The CYP46A1 enzyme serves a dedicated function in producing the brain-specific oxysterol to remove excess cholesterol from the brain [186]. 24S-HC can also facilitate cholesterol homeostasis via transcriptional regulation [45]. In situations of cholesterol excess, 24S-HC inhibits SREBP-2 to suppress cholesterol biosynthesis in glial cells [189, 190]. 24S-HC also serves as a ligand for LXR, mediating the expression of target genes encoding cholesterol transporters, ApoE, ABCA1, and ABCG1, thus promoting the distribution of cholesterol from astrocytes to neurons [191].

Other functions of 24S-HC unrelated to cholesterol metabolism include modulation of Aβ production, prevention of tau hyperphosphorylation, and induction of N-methyl-D-aspartate receptor-mediated excitotoxicity. Excess accumulation of 24S-HC may promote oxidative stress and cytotoxicity [191, 192]. 24S-HC may also be involved in the pathogenesis of neurodegenerative disorders and could be a suitable biomarker for such conditions, as its level reflects the number of metabolically active neurons in the brain [193, 194].

27-HC

While 24S-HC is the predominant oxysterol generated in the brain, the analogous oxysterol generated in the periphery is 27-HC. Excess cholesterol is converted to 27-HC by the CYP 27A1 enzyme in the first step of the alternative bile acid synthesis pathway, which can then diffuse across the blood-brain barrier into the brain at a rate of 5 mg/day [77, 195, 196]. Decreased levels of oxysterol are observed in Alzheimer’s, Parkinson’s, and Huntington’s diseases [5]. Correspondingly, treatment of primary human neurons with 27-HC has been shown to downregulate Aβ production, potentially in an LXR-mediated manner [183], suggesting that the oxysterol is a possible therapeutic target for Alzheimer’s disease. 27-HC may promote LXR activation, as the peripheral injection of the oxysterol into rats has been shown to upregulate LXRα and ABCA1 in the brain, and downregulate genes for cholesterol synthesis, and uptake [197]. However, high doses of 27-HC impair spatial memory performance [197] and further studies are required to understand how 27-HC is involved in brain function.

24,25-EC

24,25-EC is produced differently from other oxysterols; it is not derived from cholesterol but generated from sterol intermediates. Partial inhibition of the LSS enzyme channels sterol intermediates into the epoxycholesterol Shunt pathway, where epoxylanosterol is metabolized into 24,25-EC (Figure 1) [198]. In addition, desmosterol can be converted into epoxycholesterol by the action of CYP46A1 [199]. 24,25-EC is produced in human brains [200], and in rat neonate brains it is more abundant than 24S-HC [201].

24,25-EC is involved in the development and maintenance of brain function. Increasing flux in the Shunt pathway via LSS inhibition enhances oligodendrocyte formation and remyelination [202]. Overexpression of human CYP46A1 in mice increases levels of 24S-HC and 24,25-EC, and this is associated with enhanced midbrain dopamine neurogenesis [203], a process important for controlling voluntary movement, reward processing, and working memory [204]. It is uncertain whether CYP46A1 activity or the epoxycholesterol Shunt pathway is more important for 24,25-EC production in the brain, but an interplay between the two mechanisms is likely [186].